CJC-1295 / Ipamorelin Stack vs Follistatin 344
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 / Ipamorelin Stack
The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects.
Full profileFollistatin 344
Follistatin 344 is a 344-amino acid isoform of follistatin — an endogenous glycoprotein that functions primarily as a myostatin and activin inhibitor. Myostatin (GDF-8) is the body's primary muscle growth suppressor; follistatin binds and neutralizes it with high affinity, removing this brake on muscle protein synthesis. Research and animal data show dramatic increases in muscle fiber size and strength when follistatin is elevated or myostatin is inhibited.
Full profile| CJC-1295 / Ipamorelin Stack | Follistatin 344 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combination | FST-344, Follistatin isoform 344, FST |
| Evidence | FDA-approved | Research-stage |
| Dosing range | 100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols) | 50mcg–200mcg mcg, Once daily or every other day for 10–30 day cycles |
| Administration | Subcutaneous injection (both compounds), Administered together in the same injection | Subcutaneous injection, Intramuscular injection (into target muscle — local effect hypothesis) |
| Key side effects | Water retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose) | Potential FSH suppression (reproductive effects in females — may affect menstrual cycle), Accelerated hair follicle cycling (Wnt pathway involvement — theoretical hair loss concern at high doses), Joint discomfort with rapid muscle tissue growth, Limited long-term human safety data |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: CJC-1295 / Ipamorelin Stack is fda-approved, while Follistatin 344 is research-stage.
- Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; Follistatin 344 — Subcutaneous injection, Intramuscular injection (into target muscle — local effect hypothesis).
- Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); Follistatin 344 is Once daily or every other day for 10–30 day cycles.
- Research depth: this profile cites 2 sources for CJC-1295 / Ipamorelin Stack vs 3 for Follistatin 344.
How each works
CJC-1295 / Ipamorelin Stack
CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.
Follistatin 344
Follistatin's muscle effects were dramatically illustrated when mice and cattle with follistatin overexpression or myostatin knockouts developed 2–3x normal muscle mass. Human follistatin gene therapy trials (AAV-mediated) are ongoing for Becker Muscular Dystrophy, showing sustained myostatin inhibition and improved muscle function over years from a single injection. Follistatin also inhibits activin A and B (involved in muscle wasting during illness), FSH secretion (reproductive effects), and inflammatory cytokines. The 344 isoform has an extended heparin-binding domain that increases tissue retention compared to the shorter FST-288 isoform.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.